FindTrial
Sign In

Phase II study of AJG511 in patients with active ulcerative colitis

Phase II study of AJG511 in patients with active ulcerative colitis

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222245
Enrollment
Unknown
Registered
2013-10-03
Start date
2013-10-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

investigational material(s) Generic name etc : AJG511 INN of investigational material : budesonide Therapeutic category code : 239 Other agents affecting digestive organs Dosage and Administration for

Sponsors

Ajinomoto Pharmaceuticals Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with lesions not exceeding the segment from the rectum to the sigmoid colon

Exclusion criteria

Exclusion criteria: - Patients with infections and deep mycosis against which no effective antimicrobial is available. - Patients with intolerance to or a history of allergic reaction to budesonide.

Design outcomes

Primary

MeasureTime frame
Remission rate—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026